These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29557849)

  • 21. Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study.
    Wang Y; Wu J; Jiang L; Zhang X; Liu B
    Endocrine; 2022 Apr; 76(1):109-115. PubMed ID: 35094313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
    Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
    Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
    Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
    Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
    Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
    J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
    Zhao T; Liang J; Guo Z; Li J; Lin Y
    Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial.
    Qu Y; Huang R; Li L
    Ann Nucl Med; 2017 Jan; 31(1):71-83. PubMed ID: 27757803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
    Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.
    Brassard M; Borget I; Edet-Sanson A; Giraudet AL; Mundler O; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Toubert ME; Torlontano M; Benhamou E; Schlumberger M;
    J Clin Endocrinol Metab; 2011 May; 96(5):1352-9. PubMed ID: 21389143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sufficiency of a Single Negative Thyroglobulin Standard for Judging the Success of Ablation in Low- and Intermediate-risk Differentiated Thyroid Cancer: A Retrospective Study.
    Long Y; Jin J; Zhang W
    Endocr Metab Immune Disord Drug Targets; 2024; 24(10):1204-1214. PubMed ID: 38192150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence.
    Rosario PW; Xavier AC; Calsolari MR
    Thyroid; 2011 Jan; 21(1):49-53. PubMed ID: 20954820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low activity versus high activity: noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension.
    Wang C; Zhao T; Li H; Gao W; Lin Y
    Nucl Med Commun; 2017 May; 38(5):366-371. PubMed ID: 28362717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.
    Prpic M; Kruljac I; Kust D; Kirigin LS; Jukic T; Dabelic N; Bolanca A; Kusic Z
    Endocrine; 2016 Jun; 52(3):602-8. PubMed ID: 26732041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
    Liu YQ; Li H; Liu JR; Lin YS
    Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
    Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
    Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological features affecting the efficacy in
    Xu X; Li C; Yu X; Wang G; Guo Y; Ni H; Zhao W; Wang Y; Dong B
    Front Endocrinol (Lausanne); 2024; 15():1382009. PubMed ID: 39086895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early sequential changes in serum thyroglobulin after radioiodine ablation for thyroid cancer: possible clinical implications for recombinant human thyrotropin-aided therapy.
    Taïeb D; Lussato D; Guedj E; Roux F; Mundler O
    Thyroid; 2006 Feb; 16(2):177-9. PubMed ID: 16676403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of serial preablative thyroglobulin measurements: can we address the impact of thyroid remnants?
    Zhao T; Liang J; Li T; Guo Z; Vinjamuri S; Lin Y
    Nucl Med Commun; 2016 Jun; 37(6):632-9. PubMed ID: 26829063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
    Barres B; Kelly A; Kwiatkowski F; Batisse-Lignier M; Fouilhoux G; Aubert B; Dutheil F; Tauveron I; Cachin F; Maqdasy S
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3462-3472. PubMed ID: 30785995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients.
    Webb RC; Howard RS; Stojadinovic A; Gaitonde DY; Wallace MK; Ahmed J; Burch HB
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2754-63. PubMed ID: 22639291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.